Clinical Trial Update: Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This document reports an ongoing Phase 1 study of ZV0203 for patients with HER2-positive advanced solid tumors, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ZV0203

Snippet

Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd | Conditions: HER2-positive Advanced Solid Tumor | Phase 1 | Status: ENROLLING_BY_INVITATION